Evidence map›Paper›PMID 41359384›Full record

ArticleNucleic acids research2025

RECODE: a programmable guide-free C-to-U RNA editing tool.

Mizuho Ichinose, Masaru Ohta, Yasuka Shimajiri, Yumi Akaiwa, Izumi Nakamura, Miki Shimamoto, Riyo Makinoda, Soichi Ozaki, Takayuki Tamai, Nana Maekawa and 4 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mizuho IchinoseEditForce, Inc., Fukuoka 819-0395, Japan.
Masaru OhtaEditForce, Inc., Fukuoka 819-0395, Japan.
Yasuka ShimajiriEditForce, Inc., Fukuoka 819-0395, Japan.
Yumi AkaiwaEditForce, Inc., Fukuoka 819-0395, Japan.
Izumi NakamuraEditForce, Inc., Fukuoka 819-0395, Japan.
Miki ShimamotoEditForce, Inc., Fukuoka 819-0395, Japan.
Riyo MakinodaFaculty of Agriculture, Kyushu University, Fukuoka 819-0395, Japan.
Soichi OzakiEditForce, Inc., Fukuoka 819-0395, Japan.
Takayuki TamaiEditForce, Inc., Fukuoka 819-0395, Japan.
Nana MaekawaEditForce, Inc., Fukuoka 819-0395, Japan.
Minori TonomotoFaculty of Agriculture, Kyushu University, Fukuoka 819-0395, Japan.
Takahiro NakamuraEditForce, Inc., Fukuoka 819-0395, Japan.
Yusuke YagiEditForce, Inc., Fukuoka 819-0395, Japan.
Bernard GutmannEditForce, Inc., Fukuoka 819-0395, Japan.ORCID 0000-0003-4657-0925

Funding

EditForce, Inc
6 · The paper itself

Abstract

Programmable RNA cytidine deaminase tools have been developed to convert cytidine-to-uridine (C-to-U) using CRISPR systems with guide RNAs. These tools, however, have limitations such as low editing efficiency, limited targetable sequence flexibility, and off-target RNA editing. Here, we present a novel guide-free C-to-U editing tool, named RECODE (RNA Editor for C-to-U with an Optimized DYW Enzyme), based on the RNA-binding pentatricopeptide repeat proteins, naturally fused to a C-terminal DYW cytidine deaminase domain. The RECODE specificity domain was engineered to enable retargeting, while its length and sequence were optimized to reduce off-target effects. Further optimization of the C-terminal catalytic region increased both the editing activity and the translation of the edited RNA. We showed that RECODE efficiently edits a wide range of targets in human cells, without affecting adjacent cytidines. It achieved over 50% editing efficiency for most sites, except those with an upstream guanine. Furthermore, we showed that RECODE is functional in mice, with high editing efficiency observed in specific tissues such as skeletal muscles using an AAV delivery system, suggesting its therapeutic potential for various diseases.

Indexed as

CytidineCytidine DeaminaseRNA EditingUridineAnimalsCRISPR-Cas SystemsGene EditingHEK293 CellsHumansMiceRNA-Binding ProteinsRNA, Guide, CRISPR-Cas SystemsCytidineCytidine DeaminaseRNA-Binding ProteinsRNA, Guide, CRISPR-Cas SystemsUridine

Identifiers

PMID41359384
PMCPMC12684383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.